Combination Therapy for RAS-Mutant Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
RAS-mutant cancers, particularly melanomas, are difficult to treat due to resistance to targeted therapies like BRAF inhibitors, which can paradoxically activate ERK signaling, leading to systemic toxicities and tumor growth, and there is a need to sensitize these tumors to immunotherapy.
Innovation Solution
Administering a selective BRAF inhibitor (BRAFi) in combination with immunotherapy, where the BRAFi is used to activate ERK signaling effectively, potentially inducing senescence-like growth arrest in RAS-mutant cancers, and the immunotherapy can be timed or co-administered to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BRAF inhibitors are administered to treat RAS-mutant cancers, then tumor growth is inhibited initially, but ERK pathway reactivation occurs leading to resistance and systemic toxicities
Solution Approach 1:
The patent applies preliminary anti-action by administering MEK inhibitors or pan-RAF inhibitors before or concurrently with BRAF inhibitors to preemptively block the ERK pathway reactivation that would otherwise occur. This prevents the harmful feedback loop where BRAF inhibition leads to compensatory ERK activation and subsequent resistance development.
Solution Approach 2:
The patent converts the harmful paradoxical ERK activation into a beneficial therapeutic effect by using it to sensitize RAS-mutant tumors to immunotherapy. The ERK pathway reactivation, while initially harmful, is leveraged to enhance immune checkpoint blockade efficacy, transforming a resistance mechanism into a therapeutic opportunity.
2Productivity
If BRAF inhibitors are used to treat RAS-mutant cancers, then some tumor growth suppression is achieved, but the treatment is contraindicated due to induction of RAS mutant tumor growth and systemic toxicities
Solution Approach 1:
The patent merges BRAF inhibitors with MEK inhibitors or pan-RAF inhibitors and immunotherapy agents to create a combination regimen that achieves tumor growth suppression while preventing harmful side effects. The combination approach allows the benefits of BRAF inhibition to be realized while the additional agents counteract the harmful ERK reactivation and enhance anti-tumor immunity.
Solution Approach 2:
The patent introduces MEK inhibitors or pan-RAF inhibitors as intermediary agents that mediate between BRAF inhibition and ERK pathway activity. These intermediaries block the downstream compensatory mechanisms that would otherwise lead to resistance, allowing sustained BRAF inhibitor efficacy without the harmful rebound effects.
3Reliability
If MEK inhibitors or pan-RAF inhibitors are administered as single agents, then ERK activation is blocked, but they have not been approved for clinical use and limited efficacy is observed
Solution Approach 1:
The patent combines MEK inhibitors or pan-RAF inhibitors with BRAF inhibitors and immunotherapy agents to create a synergistic combination regimen. This merging of multiple therapeutic approaches overcomes the limited efficacy of single agents by addressing multiple pathways simultaneously while enhancing immune response.
Solution Approach 2:
The patent employs combination therapy that serves multiple functions: BRAF inhibitors provide initial tumor growth suppression, MEK/pan-RAF inhibitors prevent ERK reactivation and sensitize to immunotherapy, and immune checkpoint blockers enhance anti-tumor immunity. This multi-functional approach transforms a single-agent limitation into a comprehensive therapeutic strategy.
Data Source
AI summary
RAS mutation driven tumors are difficult to treat, with no targeted agents advancing to late stage clinical trials. Although immunotherapy is indicated for RAS mutant tumors, methods are needed to sensitize tumors to immunotherapy or to treat resistance to immunotherapy. Disclosed herein is a method for treating a RAS mutant cancer in a subject that involves administering to the subject a therapeutically effective amount of a BRAF inhibitor (BRAFi) in combination with immunotherapy, such as a checkpoint inhibitor. Also disclosed herein is a composition comprising a BRAFi and a checkpoint inhibitor in a pharmaceutically acceptable carrier. As disclosed herein, selective BRAF inhibition paradoxically prevents the growth of RAS mutant tumor cell lines in vitro with a consistent ERK hyperactivation and increased senescence.